Beneficial Effect of Silymarin in Ulcerative Colitis - Trial NCT06213857
Access comprehensive clinical trial information for NCT06213857 through Pure Global AI's free database. This phase not specified trial is sponsored by Tanta University and is currently Not yet recruiting. The study focuses on Ulcerative Colitis. Target enrollment is 44 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tanta University
Timeline & Enrollment
N/A
Feb 01, 2024
Mar 01, 2025
Primary Outcome
2 points or more decrease in the Mayo score from baseline
Summary
The goal of this clinical trial is to evaluate the possible beneficial effect of silymarin in
 Ulcerative Colitis adult patients receiving mesalamine. This is trial that will be conducted
 on 44 adult patients with newly diagnosed Ulcerative Colitis. Patients will be enrolled after
 obtaining an informed consent from them or their guardians.
 
 Patients will be recruited from Rajhy Hospital Outpatient Clinics and Health Insurance
 Outpatient Clinics at Mabarra Hospital in Assiut, Egypt. The patients will be randomized
 based on hospital admission days into two groups:
 
 - Group โ (control group): 22 patients will receive mesalamine (4g\day induction & 2g\day
 maintenance) only for 6 months.
 
 - Group โ ก (silymarin group): 22 patients will receive mesalamine (4g\day induction &
 2g\day maintenance) and silymarin (140 mg\day) for 6 months.
 
 The primary outcome will be clinical improvement defined as a 2 point or more decrease in the
 Mayo score from baseline. The secondary outcomes will be the change in the level of fecal
 calprotectin, superoxide dismutase and TNF-ฮฑ.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06213857
Non-Device Trial